Indeed, in another study involving KrasG12D-driven genetically engineered mouse models of NSCLC and PDAC, dual MEK (Cobimetinib) and ERK (GDC-0994) inhibition reduced tumor growth and increased progression-free survival, but the animals still died of the tumors, indicative of the emergence of drug resistance [33]. This evidence concerns the gene MAPK1 and non-small cell lung carcinoma.